Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA CAR-T for Dynamic High-risk Multiple Myeloma
NCT06880393Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of anti-BCMA CAR-T in multiple myeloma (MM), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Mar 2025; status: recruiting.
02
Drugs
anti-BCMA CAR-T
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06880393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06880393.